Your session is about to expire
← Back to Search
KPT-9274 for Acute Myeloid Leukemia
Study Summary
This trial will study a new drug to treat patients with a certain type of leukemia that has returned or does not respond to other treatments.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I don't have severe GI issues that could affect medication absorption.My AML has not improved or has returned after treatment, and no standard treatments are likely to help.I have an infection that hasn't improved with treatment.I have severe heart disease.I am not pregnant or breastfeeding.I have an active brain or spinal cord disease.I am 18 years old or older.My white blood cell count is high, but I can use treatments to lower it for eligibility.I have an active hepatitis infection or tested positive for hepatitis B or C.I can take care of myself and am up and about more than half of the day.I haven't had cancer treatments, except hydroxyurea, in the last 2 weeks.I have recovered from side effects of my previous treatment, except for hair loss.
- Group 1: Cohort 5; 100mg
- Group 2: De-escalation Cohort; 20mg
- Group 3: Cohort 1; 30 mg
- Group 4: Cohort 2; 40mg
- Group 5: Cohort 3; 60mg
- Group 6: Cohort 4; 80mg
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many human subjects are engaged in this experiment?
"Affirmative, the clinicaltrials.gov website verifies that this investigation is currently enrolling members. The trial was initially published on August 27th 2021 and has been modified as recently as August 31st 2022. They are welcoming a total of 40 volunteers at 2 medical facilities."
How does the 30mg dosage of Cohort 1 impact patient safety?
"Cohort 1; 30 mg has been granted a safety rating of 1 due to the limited clinical evidence that exists for its efficacy and potential dangers."
Are there any vacancies in this research program for participants?
"Clinicaltrials.gov states that this research is currently enlisting participants, with initial posting occuring on August 27th 2021 and the latest update being made on August 31st 2022."
Share this study with friends
Copy Link
Messenger